Search

everythinglearnresearchcommunity

for

Search:↓

No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

A man treated with gefitinib for lung cancer grew new hair on his bald scalp.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.

Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.

Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

Ivarmacitinib effectively regrows hair in severe alopecia areata.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

Oral tofacitinib successfully treated a girl's severe skin and hair conditions.

Tofacitinib may help treat both alopecia areata and inflammatory bowel disease.

A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

The combination treatment showed a higher response rate but no significant survival benefits.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.

Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.

Dacomitinib can cause nail and skin issues, but these can be managed without stopping the drug.

A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.

Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.

Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.

Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.

Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.

Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.